Management

David Meek brings over 30 years of experience in the biopharmaceutical industry, where he has held key leadership positions across a range of publicly traded and private biotech companies. Most recently, Mr. Meek served as the Chief Executive Officer and a member of the Board of Directors at Mirati Therapeutics, Inc., a commercial-stage oncology biotech company. Mirati was acquired by Bristol Myers Squibb for $5.8 billion.

Prior to his tenure at Mirati, Mr. Meek was the CEO and a Board Member of FerGene, Inc., a private biotech company, from 2020 to 2021. From 2016 to 2020, he led Ipsen, a biopharmaceutical company headquartered in Paris, France, as its Chief Executive Officer and Board Member. Mr. Meek also held significant executive roles, including Executive Vice President and President of Oncology at Baxalta Inc., where he oversaw the oncology division through its acquisition by Shire. Earlier in his career, he served as Chief Commercial Officer at Endocyte, Inc., and held various executive positions at Novartis Pharmaceuticals and Novartis Oncology, following his initial roles at Johnson & Johnson and Janssen Pharmaceuticals.

Currently, Mr. Meek serves on the Boards of Directors for Cullinan Therapeutics Inc. and uniQure N.V., both publicly traded biotech companies. He is also a Board of Councilors member for the University of Southern California Mann School of Pharmacy and Pharmaceutical Sciences. His previous board roles include positions with the Pharmaceutical Research & Manufacturers of America (PhRMA), the European Federation of Pharmaceutical Industries & Associations, Fusion Pharmaceuticals Inc. (acquired by AstraZeneca), and Entasis Therapeutics Inc. (acquired by Innoviva, Inc.).

Mr. Meek holds a Bachelor of Arts degree from the University of Cincinnati.

Dr. Burns is the scientific founder of Aminex. Mark earned a PhD at the University of Michigan and post-doctoral training in bio-organic chemistry at Rice University. During his over 20 years of experience in biotechnology Mark led the discovery efforts resulting in Aminex’s AMXT 1501/DFMO assets. Mark has obtained 15 U.S. Patents and published 21 scientific papers. He has extensive experience in the fields of medicinal, combinatorial, enzyme inhibitor design, analytical and process chemistry.

Jeff Judson has a cross-cutting responsibility at Aminex in investor recruitment, regulatory oversight, communications, and project management. His career spans 35 years of working on Capitol Hill, studying and influencing public and regulatory policy at all levels of government as a think tank president and later assisting corporations and trade associations to overcome regulatory obstacles.

Brent Meadows joined Aminex Therapeutics in October 2025 as Chief Business Officer responsible for partnering and collaboration efforts.

An industry veteran with senior leadership experience at Johnson & Johnson, Bristol Myers Squibb, Regeneron, Biogen, and multiple oncology-focused biotechnology companies, Brent has played a central role in the global launch and lifecycle strategy of novel oncology and immuno-oncology agents, spanning both solid tumors and hematologic malignancies. His experience includes building and leading launch marketing organizations, structuring complex in- and out-licensing transactions, and supporting assets from early-stage development through FDA and EMA approval and launch uptake.

Notably, Brent was directly involved in the in-licensing of Johnson & Johnson’s first externally sourced oncology therapeutic, which ultimately achieved regulatory approval in both the U.S. and Europe. At AVEO Oncology, Brent was the commercial point on the $1.4 billion co-commercialization and co-development collaboration with Astellas for FOTIVDA® (tivozanib), a novel cancer therapeutic which went on to FDA and EMA approvals. Brent also worked to help secure Baxalta’s strategic immuno-oncology and allogenic CAR-T in-licensing collaborations with Symphogen and Precision Biosciences respectively. Most recently in 2025, Brent led the global out-licensing collaboration between Polymed Biopharmaceuticals (Hangzhou, China) and Photys Therapeutics (Waltham, MA) for Polymed’s IRAK4 PROTAC targeting multiple immunology maladies.

Driven by a conviction that transformative cancer therapies reach patients fastest when scientific differentiation, clinical strategy, and value creation are tightly aligned, Brent now serves as a fractional Chief Business Officer advising multiple cutting-edge oncology-focused companies. In this capacity, he helps leadership teams translate complex tumor immunology into clear strategic narratives, define development and partnering strategies, and execute high-impact collaborations with leading pharmaceutical companies, academic centers, and investors—particularly within the Boston/Cambridge ecosystem and globally.

Brent received his Bachelor’s of Science in Business Administration from the University of Richmond and his Masters of Business from Babson College. He resides in the Boston area with his wife, Elizabeth, and their Springer Spaniel, Sadie.

Jacquelyn Wright, MS, PMP, is a seasoned pharmaceutical professional with over 30 years of industry experience. She has held key roles at leading organizations including Schering-Plough, Merck, Novartis, and most recently, Amicus Therapeutics. Jacquelyn has successfully led global clinical teams across all phases of drug development—from first-in-human through Phase 4— with a particular focus on pivotal Phase 3 trials. Her work has contributed to regulatory approvals by both the FDA and EMA. With expertise in both adult and pediatric drug development, Jacquelyn brings a strong foundation in Clinical Operations and strategic execution, enhanced by her certification as a Project Management Professional (PMP).

Deyaa Adib, M.D. has over 28 years of experience in the biotechnology and pharmaceutical industries in multidisciplinary oncology and immuno-oncology from drug research, through commercialization experience with 7 global registrations including Taxotere, Eloxatin, Xtandi, Oncaspar, Tazverick, Onivyde and Eclusig in multiple indications across hematologic malignancies and solid tumors. Currently serving as the Chief Medical Officer at AffyImmune advancing a CAR-T cell therapy program towards registration in anaplastic thyroid cancer via successful FDA interactions and financing rounds.

Previously, he served as SVP & Chief Medical Officer at FibroGen (NASDAQ FGEN) leading the development of late stage 1st in class mAB (CTGF) and an ADC (CD46) in pancreatic cancer and prostate cancer indications and previously the CMO for Triumvira Immunologics leading the development of early and mid stage TCR (TAC-T) autologous cell therapies for multiple targets in GI solid tumors and securing multiple financing rounds. Dr. Adib served as Acting CMO at Rain Therapeutics advancing the organization from the private into public sector via licensing deals leading to a successful IPO.

Before that, he was the Vice President of late-stage development at Blueprint Medicines advancing the devleopment of avaprinitnib towards registration in GIST. Dr. Adib also served as Global Therapeutics Head for solid tumors at Baxalta building the oncology portfolio from the ground up and advancing the development of nano-liposomal irinotecan towards approval in pancreatic cancer, pegasparage in ALL and securing multiple licensing/M&A opportunities in the I-O space leading to the acquisition by Shire for 11.2 Billion for the oncology portfolio. He also served as Head of Hematologic Malignancies at ARIAD Pharmaceuticals repositioning ponatinib & brigatinib from local into global domain hence, securing the acquisition by Takeda for 5.2 Billion . Earlier in his career, he held multiple oncology clinical development leadership positions at Aventis, Sanofi and Astellas Pharma. Dr. Adib obtained an M.B., B.Ch. (M.D.) degree from Cairo University School of Medicine in Cairo, Egypt. He completed his postgraduate medical oncology training at the Anglo-American Cancer Institute in Cairo and at Tufts University School of Medicine, Boston, MA, in clinical pharmacology, drug development and regulation. He completed his research fellowship in cancer immunology at St. Joseph’s Hospital & Medical Center in Paterson, New Jersey.

Victoria (Vicki) Demby is a global regulatory affairs consultant and the US Authorized regulatory Agent for Aminex Therapeutics, Inc. She possesses deep expertise in drug development and regulatory affairs, built through a progressive career in global regulatory roles at top pharmaceutical companies including Bristol Myers Squibb, Merck, and GlaxoSmithKline. Most recently, she held the position of Senior Vice President of Global Regulatory Affairs at Adlai Nortye, USA, Inc., where she was a member of the executive leadership team, leading the development and execution of global regulatory strategies across the company’s pipeline.

Throughout her career, Victoria has played a pivotal role in achieving regulatory approvals for a wide range of impactful therapies across diverse therapeutic areas. These include NULOJIX®, ORENCIA®, ELIQUIS®, MARIZEV®, JANUVIA®, JANUMET®, JANUMET XR®, and the landmark cancer immunotherapy KEYTRUDA®. She earned her Bachelor of Science in Biochemistry from the University of Vermont and completed her PhD in Pharmacology and Toxicology at the University of Kansas.